Tilray | TRLY - Current Liabilities


Tilray reported $259.32M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acasti Pharma USD 1.24M 1.08M Sep/2025
Akebia Therapeutics USD 162.94M 29.56M Dec/2025
Alaunos Therapeutics USD 921K 153K Sep/2025
Aurora Cannabis CAD 145.94M 21.82M Dec/2025
Avita Medical AUD 62.68M 77K Dec/2025
Canopy Growth CAD 98.29M 17.19M Dec/2025
Cronos Group USD 48.19M 7.12M Dec/2025
Dianthus Therapeutics USD 30.73M 6.88M Dec/2025
Divis Laboratories Ltd INR 17.28B 2.76B Sep/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
IQVIA Holdings USD 8.34B 170M Dec/2025
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Moderna USD 1.99B 306M Dec/2025
Organigram Holdings CAD 94.05M 32.11M Dec/2025
Organon & Co USD 2.68B 117M Sep/2025
Revvity USD 1.33B 108.5M Dec/2025
Tectonic Therapeutic USD 9.67M 293K Dec/2025
Tilray USD 259.32M 8.32M Sep/2025
Viatris USD 7.09B 269.8M Dec/2025
Xeris Pharmaceuticals USD 109.57M 6.63M Dec/2025
Zealand Pharma A/S 664.96M 513.61M Dec/2025